# Alkermes

> Alkermes is a Dublin-headquartered, Nasdaq-listed biopharmaceutical company focused on neuroscience. It sells medicines in the United States for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, while developing orexin 2 receptor agonists for sleep, attention and fatigue disorders. Its commercial portfolio, specialized U.S. infrastructure, Ohio manufacturing operation and legacy drug-delivery technologies create a hybrid business spanning proprietary product sales, manufacturing and royalty income.

- **Founded:** 1987
- **Headquarters:** Dublin, Ireland
- **Founders:** Michael Wall (Founder and original chairman)
- **Team size:** Approximately 2,050 full-time employees as of February 20, 2026, including the acquired Avadel organization; about 1,950 were based in the U.S. and 100 in Ireland.
- **Products:** VIVITROL, ARISTADA, ARISTADA INITIO, LYBALVI, LUMRYZ
- **Notable:** Built a proprietary commercial portfolio spanning addiction, serious mental illness and narcolepsy., Reported $1.475899 billion in total revenue for 2025., Completed the separation of Mural Oncology in 2023 to become a neuroscience-focused company.

## Products & services

- **VIVITROL** — A once-monthly extended-release injectable naltrexone used for alcohol dependence and for prevention of relapse to opioid dependence after opioid detoxification.
- **ARISTADA** — A long-acting injectable aripiprazole lauroxil medicine for schizophrenia in adults, offered across several dosing intervals.
- **ARISTADA INITIO** — A one-time initiation regimen used with oral aripiprazole to begin or restart ARISTADA treatment.
- **LYBALVI** — A once-daily combination of olanzapine and samidorphan for adults with schizophrenia or bipolar I disorder.
- **LUMRYZ** — A once-at-bedtime extended-release sodium oxybate treatment for cataplexy or excessive daytime sleepiness in people age seven and older with narcolepsy; added through the 2026 Avadel acquisition.
- **Alixorexton** — An investigational oral selective orexin 2 receptor agonist in phase 3 for narcolepsy types 1 and 2 and phase 2 for idiopathic hypersomnia.
- **ALKS 4510** — An investigational orexin 2 receptor agonist in phase 1 for fatigue associated with multiple sclerosis and Parkinson's disease.
- **ALKS 7290** — An investigational orexin 2 receptor agonist in phase 1 for attention-deficit hyperactivity disorder.
- **Valiloxybate** — An investigational GABA-B receptor agonist in phase 1 for narcolepsy and idiopathic hypersomnia.
- **Drug-delivery licensing and manufacturing** — Alkermes licenses formulation technologies used in third-party medicines and receives manufacturing revenue and royalties under selected arrangements.

## Achievements

- Built a proprietary commercial portfolio spanning addiction, serious mental illness and narcolepsy.
- Reported $1.475899 billion in total revenue for 2025.
- Completed the separation of Mural Oncology in 2023 to become a neuroscience-focused company.
- Completed the acquisition of Avadel Pharmaceuticals in February 2026 for consideration of up to approximately $2.37 billion.
- Advanced alixorexton into phase 3 Brilliance studies for narcolepsy types 1 and 2 in 2026.
- Received FDA Breakthrough Therapy designation for alixorexton in narcolepsy type 1 and U.S. and European orphan designations in sleep disorders.
- Operates an integrated U.S. R&D, commercial and GMP manufacturing footprint.
- Recognized in 2025 by Fortune as a Best Workplace in Biotech and Pharmaceuticals and by regional workplace lists in Massachusetts, Ireland and Greater Cincinnati.

## Latest updates

- **2026-07** — Reported interim long-term-extension data showing sustained improvements in wakefulness, sleepiness, cognition and fatigue with investigational alixorexton through roughly nine months in adults with narcolepsy types 1 and 2.
- **2026-07** — Reported second-quarter 2026 results for the first full quarter to include LUMRYZ following the Avadel acquisition.
- **2026-06** — Alixorexton received U.S. orphan designation for idiopathic hypersomnia and European orphan designation for narcolepsy.
- **2026-05** — The REVITALYZ phase 3 study of LUMRYZ in adults with idiopathic hypersomnia produced positive topline results.
- **2026-04** — Initiated the phase 3 Brilliance studies of alixorexton in narcolepsy types 1 and 2.
- **2026-02** — Completed the acquisition of Avadel Pharmaceuticals, adding LUMRYZ and a sleep-medicine commercial team.
- **2026-02** — Announced that Blair Jackson would become CEO on August 1, 2026, succeeding 35-year CEO Richard Pops, who remains chairman.

## Links

- Website: https://www.alkermes.com/
- LinkedIn: https://www.linkedin.com/company/alkermes
- Twitter/X: https://twitter.com/alkermes
- YouTube: https://www.youtube.com/channel/UC1CXRHrg3JzXO962jQctF7w
- Facebook: https://facebook.com/Alkermes-Incorporated-164936140199457/

---

Profile page: https://yespress.io/alkermes
Published by YesPress — https://yespress.io
Last updated: 2026-08-11